蛋白激酶 C 亚型 δ 调控糖尿病动脉粥样硬化中的血管生物学。

Department of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Cell Commun Signal. 2023 Nov 16;21(1):330. doi: 10.1186/s12964-023-01361-4.

Diabetes mellitus, known for its complications, especially vascular complications, is becoming a globally serious social problem. Atherosclerosis has been recognized as a common vascular complication mechanism in diabetes. The diacylglycerol (DAG)-protein kinase C (PKC) pathway plays an important role in atherosclerosis. PKCs can be divided into three subgroups: conventional PKCs (cPKCs), novel PKCs (nPKCs), and atypical PKCs (aPKCs). The aim of this review is to provide a comprehensive overview of the role of the PKCδ pathway, an isoform of nPKC, in regulating the function of endothelial cells, vascular smooth muscle cells, and macrophages in diabetic atherosclerosis. In addition, potential therapeutic targets regarding the PKCδ pathway are summarized. Video Abstract.

糖尿病，以其并发症为特征，尤其是血管并发症，正成为一个全球性的严重社会问题。动脉粥样硬化已被认为是糖尿病的一种常见血管并发症机制。二酰基甘油（DAG）-蛋白激酶 C（PKC）途径在动脉粥样硬化中起重要作用。PKC 可分为三个亚组：传统 PKC（cPKC）、新型 PKC（nPKC）和非典型 PKC（aPKC）。本综述的目的是全面概述新型 PKC 同工型 PKCδ途径在调节糖尿病动脉粥样硬化中内皮细胞、血管平滑肌细胞和巨噬细胞功能中的作用。此外，还总结了 PKCδ途径的潜在治疗靶点。视频摘要。